(Q38813080)

English

Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab

scientific article published on 9 October 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab (English)

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

phase III clinical trial

0 references

systemic lupus erythematosus

0 references

pharmacodynamics

1 reference

based on heuristic

inferred from title

Marta E Alarcón-Riquelme

3

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Michelle A. Petri

4

object named as

Michelle Petri

1 reference

Europe PubMed Central

2 July 2019

2

object named as

Joan T Merrill

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

object named as

Yushi Liu

13

0 references

author name string

Robert W Hoffman

1

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Ernst R Dow

5

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Eric Nantz

6

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Laura K Nisenbaum

7

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Krista M Schroeder

8

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Wendy J Komocsar

9

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Narayanan B Perumal

10

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Matthew D Linnik

11

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

David C Airey

12

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Guilherme V Rocha

14

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Richard E Higgs

15

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

publication date

1 March 2017

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Arthritis & Rheumatology

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

69

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

3

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

643-654

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Regulated expression of BAFF-binding receptors during human B cell differentiation.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controll

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Diagnosis and risk stratification in patients with anti-RNP autoimmunity.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Combined oral contraceptives in women with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Genetic susceptibility to systemic lupus erythematosus in the genomic era

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

The genetics of lupus: a functional perspective

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Summaries of Affymetrix GeneChip probe level data

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Direct multiplexed measurement of gene expression with color-coded probe pairs

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

WGCNA: an R package for weighted correlation network analysis

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Is my network module preserved and reproducible?

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Sample Sizes Required to Detect Interactions between Two Binary Fixed-Effects in a Mixed-Effects Linear Regression Model

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Human housekeeping genes, revisited

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha identifies multiple novel loci involved in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Genetic analyses of interferon pathway-related genes reveal multiple new loci associated with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Towards the taxonomy of human disease.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Densely interconnected transcriptional circuits control cell states in human hematopoiesis

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/27723281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The plasma cell signature in autoimmune disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/27723281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.39950

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38813080&oldid=2144075679"